Related Experiment Video
Updated: Aug 23, 2026

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
Published on: June 11, 2020
Myocardial protection at a crossroads: the need for translation into clinical therapy
Roberto Bolli1, Lance Becker, Garrett Gross
1Heart Research Program, Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health & Human Services, Bethesda, Md 20892, USA.
Abstract:
Over the past 30 years, hundreds of experimental interventions (both pharmacologic and nonpharmacologic) have been reported to protect the ischemic myocardium in experimental animals; however, with the exception of early reperfusion, none has been translated into clinical practice. The National Heart, Lung, and Blood Institute convened a working group to discuss the reasons for the failure to translate potential therapies for protecting the heart from ischemia and reperfusion and to recommend new approaches to accomplish this goal. The Working Group concluded that cardioprotection in the setting of acute myocardial infarction, cardiac surgery, and cardiac arrest is at a crossroads. Present basic research approaches to identify cardioprotective therapies are inefficient and counterproductive. For 3 decades, significant resources have been invested in single-center studies that have often yielded inconclusive results. A new paradigm is needed to obviate many of the difficulties associated with translation of basic science findings. The Working Group urged a new focus on translational research that emphasizes efficacy and clinically relevant outcomes, and recommended the establishment of a system for rigorous preclinical testing of promising cardioprotective agents with clinical trial-like approaches (ie, blinded, randomized, multicenter, and adequately powered studies using standardized methods). A national preclinical research consortium would enable rational translation of important basic science findings into clinical use. The Working Group recommended that the National Institutes of Health proactively intervene to remedy current problems that impede translation of cardioprotective therapies. Their specific recommendations include the establishment of a preclinical consortium and the performance of 2 clinical studies that are likely to demonstrate effectiveness (phase III clinical trials of adenosine in acute myocardial infarction and cardiac surgery).
Insights
Translating cardioprotective therapies from animal studies to human clinical practice has failed. A new focus on rigorous preclinical testing and multicenter trials is needed for effective heart protection strategies.
Area of Science:
- Cardiovascular Research
- Translational Medicine
- Pharmacology
Background:
- Hundreds of experimental cardioprotective interventions for ischemic myocardium have not translated to clinical practice over 30 years.
- Existing basic research approaches are inefficient, leading to inconclusive results from single-center studies.
- Cardioprotection for acute myocardial infarction, cardiac surgery, and arrest is at a critical juncture.
Purpose of the Study:
- To identify reasons for the failure in translating cardioprotective therapies from animal models to human clinical practice.
- To recommend new approaches for effective translation of basic science findings into clinical use.
- To establish a new paradigm for cardioprotective research and development.
Main Methods:
- Convened a National Heart, Lung, and Blood Institute working group to discuss translation challenges.
- Reviewed existing basic research and preclinical testing methodologies.
- Proposed a new translational research framework emphasizing efficacy and clinical outcomes.
Main Results:
- Current basic research methods for identifying cardioprotective therapies are inefficient and counterproductive.
- Significant investment in single-center studies has yielded inconclusive results.
- A new paradigm focusing on rigorous preclinical testing is essential for successful translation.
Conclusions:
- A new focus on translational research with clinically relevant outcomes is urgently needed.
- Establishment of a national preclinical research consortium for rigorous testing is recommended.
- NIH intervention is recommended, including a preclinical consortium and Phase III trials of adenosine.
More Related Videos
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Myocarditis III: Medical Management
Cardiomyopathy II: Dilated Cardiomyopathy
Atherosclerosis III: Management
Coronary Artery Disease V: Interprofessional Care
Myocarditis I: Introduction

